Phase II Trial of Vorinostat in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study

PURPOSE: Vorinostat, a histone deacetylase inhibitor, represents a rational therapeutic target in glioblastoma multiforme (GBM). PATIENTS AND METHODS: Patients with recurrent GBM who had received one or fewer chemotherapy regimens for progressive disease were eligible. Vorinostat was administered at...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Galanis, Evanthia, Jaeckle, Kurt A., Maurer, Matthew J., Reid, Joel M., Ames, Matthew M., Hardwick, James S., Reilly, John F., Loboda, Andrey, Nebozhyn, Michael, Fantin, Valeria R., Richon, Victoria M., Scheithauer, Bernd, Giannini, Caterina, Flynn, Patrick J., Moore, Dennis F., Zwiebel, James, Buckner, Jan C.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Clinical Oncology 2009
Témata:
Original Reports
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2669764/
https://ncbi.nlm.nih.gov/pubmed/19307505
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.19.0694
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky